Introduction: Adalimumab (ADA), a fully humanized antibody against tumor necrosis factor (TNF)-α, has revolutionized the treatment of patients with juvenile idiopathic arthritis (JIA). Here, TNF is linked to juvenile idiopathic arthritis.